Understanding the Pathophysiology and Burden of COPD With Blood Eosinophils as a Marker of T2 Inflammation – Is it the Time for Precision Medicine in COPD?

May 20 @ 1:00 pm 1:45 pm PDT

Innovation Theater 3
Supported By: GSK

Chronic obstructive pulmonary disease (COPD) is a common, complex, and heterogeneous condition with considerable morbidity, mortality, and healthcare expense. In this program, the impact of exacerbations and existing unmet needs in COPD will be discussed. Additionally, the pathologic evidence for eosinophils as marker of T2 inflammation in COPD and their use as a biomarker and prognostic indicator will be reviewed within the framework of the concept of precision medicine.

An Industry Program presentation at the ATS 2024 International Conference. This program is sponsored by GSK and is open to all ATS 2024 International Conference attendees. This information is scientific and non-promotional in nature.

Presenter: Frank Sciurba, MD, FCCP
University of Pittsburgh Medical Center
Pulmonary, Allergy, and Critical Care Medicine
Professor of Medicine and Education
Pittsburgh, Pennsylvania

Emphysema/COPD Research Center
Pittsburgh, Pennsylvania

Mona Bafadhel, MBChB, PhD, FRCP
King’s College London
Professor of Respiratory Medicine
London, England

Nicola Hanania, MD, MS
Baylor College of Medicine
Professor of Pulmonary Medicine
Director, Airways Clinical Research Center
Member, Vice Chair of Research Group
Houston, TX